Research programme: antiviral vaccines - Vaxart

Drug Profile

Research programme: antiviral vaccines - Vaxart

Alternative Names: Chikungunya virus vaccine - Vaxart; Hepatitis B vaccine - Vaxart; Herpes simplex virus vaccine - Vaxart; Human papillomavirus vaccine - Vaxart; Zika virus vaccine - Vaxart

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxart
  • Class Hepatitis B vaccines; Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chikungunya virus infections; Herpes simplex virus type 2 infections; Zika virus infection
  • No development reported Hepatitis B; Herpes simplex virus infections; Human papillomavirus infections

Most Recent Events

  • 21 Apr 2018 Preclinical trials in Chikungunya virus infections (Prevention) in USA before April 2018
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (PO)
  • 03 Mar 2016 Preclinical trials in Zika virus infection (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top